• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies".关于“伊布替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：临床研究的荟萃分析”的评论
BMC Pharmacol Toxicol. 2025 Apr 11;26(1):80. doi: 10.1186/s40360-025-00923-1.
2
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。
Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.
3
Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：临床研究的荟萃分析
BMC Pharmacol Toxicol. 2025 Feb 25;26(1):43. doi: 10.1186/s40360-024-00832-9.
4
Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.在美国接受治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者按治疗线和种族划分的真实世界治疗模式和结局：前瞻性、观察性 informCLL 登记研究的最终分析结果。
Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):e301-e313. doi: 10.1016/j.clml.2024.05.009. Epub 2024 May 13.
5
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.RESONATE-2™ 和 RESONATE™ 研究中单药伊布替尼与真实世界 PHEDRA 数据库中治疗慢性淋巴细胞白血病患者的治疗方案相比。
Ann Hematol. 2019 Dec;98(12):2749-2760. doi: 10.1007/s00277-019-03830-8. Epub 2019 Nov 19.
6
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).依鲁替尼与利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的真实世界分析：来自慢性淋巴细胞白血病患者登记处（CLLEAR）的研究。
Br J Haematol. 2023 Jul;202(1):40-47. doi: 10.1111/bjh.18736. Epub 2023 Mar 27.
7
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).在同情使用项目中治疗复发或难治性慢性淋巴细胞白血病的患者中停用伊布替尼：来自波兰成人白血病研究组（PALG）的报告。
Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911.
8
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.伊布替尼治疗一线和复发/难治性慢性淋巴细胞白血病：关键性 Ib/II 期 PCYC-1102 研究的最终分析。
Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24.
9
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.伊布替尼与利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤：一项随机、开放标签的 3 期研究。
Cancer Med. 2018 Apr;7(4):1043-1055. doi: 10.1002/cam4.1337. Epub 2018 Mar 13.
10
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.Umbralisib联合伊布替尼治疗复发或难治性慢性淋巴细胞白血病或套细胞淋巴瘤患者：一项多中心1-1b期研究
Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

本文引用的文献

1
Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：临床研究的荟萃分析
BMC Pharmacol Toxicol. 2025 Feb 25;26(1):43. doi: 10.1186/s40360-024-00832-9.
2
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.医疗保险受益人与慢性淋巴细胞白血病患者的治疗模式差异：对患者和环境因素的分析。
Leuk Lymphoma. 2024 May;65(5):598-608. doi: 10.1080/10428194.2024.2310150. Epub 2024 Feb 7.
3
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers.慢性淋巴细胞白血病的治疗抵抗：新老分子生物标志物。
Int J Mol Sci. 2023 Jun 20;24(12):10374. doi: 10.3390/ijms241210374.
4
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.伊布替尼治疗慢性淋巴细胞白血病患者的真实世界临床结局和不良事件：一项单中心回顾性研究。
Medicina (Kaunas). 2023 Feb 9;59(2):324. doi: 10.3390/medicina59020324.
5
Heterogeneity in treatment effects across diverse populations.不同人群治疗效果的异质性。
Pharm Stat. 2021 Sep;20(5):929-938. doi: 10.1002/pst.2161. Epub 2021 Aug 16.

Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies".

作者信息

Namdar Ali Beheshti, Keikha Masoud

机构信息

Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Tropical and Communicable Diseases Research Center, Iranshahr University of Medical Sciences Iranshahr, Iranshahr, Iran.

出版信息

BMC Pharmacol Toxicol. 2025 Apr 11;26(1):80. doi: 10.1186/s40360-025-00923-1.

DOI:10.1186/s40360-025-00923-1
PMID:40217376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11992757/
Abstract
摘要